Dr. Reddy's halves semaglutide supply guidance after API impurity
An API impurity in validation batches forces Dr. Reddy's to cut FY27 pen target from 12M to 6-7M. Commercial supply to partner One Source now expected in October, retail from November.
— 2 earlier stories on Dr. Reddy's Laboratories Ltd. →What's new
- Root cause identified in process parameters; expected within two weeks.
- Three validation batches targeted by end-September; commercial supply to One Source in October.
- FY27 supply guidance halved to 6-7 million pens; long-term EBITDA margin target unchanged.
- Write-down on unsold inventory expected to be disclosed with Q1 results.
Why this matters
The generic semaglutide launch is one of Dr. Reddy's most anticipated catalysts. Cutting the first-year supply target by half signals a material revenue delay and a competitive opening for rivals. The write-down will hit near-term profits, but the strong demand backdrop and unchanged margin targets suggest management views this as a fixable setback, not a structural problem.
What we're watching
- Q1 results for the inventory write-down amount.
- Root cause confirmation within the two-week deadline.
- Whether competitors accelerate their generic semaglutide timelines.
The full read
Dr. Reddy's laid out a clear but costly timeline to fix the semaglutide manufacturing issue. An API impurity, caught in validation batches, has delayed commercial supply by months and forced management to cut FY27 guidance from 12 million pens to 6-7 million pens. Root cause is expected within two weeks; three validation batches by end-September; commercial supply to partner One Source in October; retail from November. The company will also take a write-down on unsold inventory, to be revealed with Q1 results. The demand narrative remains intact — strong and exceeding industry capacity — and long-term EBITDA margin targets are unchanged. But cutting the first-year supply target in half hands competitors a window. For a stock trading at 27x trailing earnings, the revenue delay matters more than the one-time charge. The next test: whether the root cause fix holds and production can accelerate to reclaim lost volume.
Questions answered
- What caused the halt in commercial supply of semaglutide?
- An impurity was found in validation batches, traced to process parameters during formulation. The issue was caught before any batches reached the market.
- When does Dr. Reddy's expect to resume commercial supply?
- Three validation batches are expected by end-September, commercial supply to partner One Source in October, and retail market resumption from November.
- How much has the FY27 supply guidance been cut?
- The initial annual target of 12 million pens has been reduced to 6-7 million pens for FY27.
- Will there be a financial charge related to this issue?
- Yes, Dr. Reddy's expects to book a write-down on unsold inventory, which will be disclosed with its first-quarter results.
- Is the demand for semaglutide still strong according to management?
- Yes, management stated that underlying demand for semaglutide is strong and exceeds industry capacity.
- Have long-term margin targets changed?
- No, the company's long-term EBITDA margin goals remain unchanged despite the supply revision.
Dr. Reddy's Laboratories Ltd.
Latest quarter · Mar 2026
Strength & growth
Story so far
All notes on DRREDDY →- 9 Jul 2026 · 5:23 PM IST Dr. Reddy's halves semaglutide supply guidance after API impurity
- 1d ago Dr. Reddy's delays generic semaglutide supply after API issue
- 27d ago Dr. Reddy's launches first generic Bosulif analogue with 180-day US exclusivity